First trimester screening for aneuploidy: Serum biochemical markers

被引:29
作者
Canick, JA
Kellner, LH
机构
[1] Women & Infants Hosp, Div Prenatal & Special Testing, Providence, RI 02905 USA
[2] Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA
[3] Montefiore Med Ctr, Reprod Genet Lab, Bronx, NY 10467 USA
[4] Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY 10467 USA
关键词
D O I
10.1016/S0146-0005(99)80002-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The article reviews screening for Down syndrome in the first trimester (8-13 gestational weeks) with maternal serum analytes. In the first trimester, 2 serum markers stand out: pregnancy-associated plasma protein-A, a large glycoprotein tetramer, and free β-human chorionic gonadotropin (β- hCG), 1 of the 2 subunits of the glycoprotein hormone hCG. Some data indicate that hCG itself may be as effective as free β-hCG in the first trimester. Maternal serum levels of pregnancy-associated plasma protein-A are low and free β-hCG are high (consensus multiple of the medians, 0.4 and 1.8, respectively) in Down syndrome pregnancy. The consensus estimate of screening performance by using pregnancy-associated plasma protein-A and free β-hCG in combination with maternal age is 60% detection rate at a 5% false positive rate. This is similar to the screening performance of second trimester double markers, but not as good as the screening performance of second trimester triple or quad markers. For this reason, first trimester screening with serum markers alone cannot be recommended except in cases in which second trimester screening cannot be done.
引用
收藏
页码:359 / 368
页数:10
相关论文
共 74 条
[1]   1ST-TRIMESTER BIOCHEMICAL SCREENING FOR FETAL CHROMOSOME-ABNORMALITIES AND NEURAL-TUBE DEFECTS [J].
AITKEN, DA ;
MCCAW, G ;
CROSSLEY, JA ;
BERRY, E ;
CONNOR, JM ;
SPENCER, K ;
MACRI, JN .
PRENATAL DIAGNOSIS, 1993, 13 (08) :681-689
[2]  
AITKEN DA, 1993, 4 C END MET HUM REPR
[3]   Screening for Down's syndrome: Changes in marker levels and detection rates between first and second trimesters [J].
Berry, E ;
Aitken, DA ;
Crossley, JA ;
Macri, JN ;
Connor, JM .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (07) :811-817
[4]   MATERNAL SERUM SCREENING FOR DOWNS-SYNDROME IN THE FIRST TRIMESTER OF PREGNANCY [J].
BIAGIOTTI, R ;
CARIATI, E ;
BRIZZI, L ;
DAGATA, A .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1995, 102 (08) :660-662
[5]  
Biagiotti R, 1998, PRENATAL DIAG, V18, P907, DOI 10.1002/(SICI)1097-0223(199809)18:9<907::AID-PD371>3.0.CO
[6]  
2-1
[7]   First trimester screening for Down's syndrome using maternal serum PAPP-A and free β-hCG in combination with fetal nuchal translucency thickness [J].
Biagiotti, R ;
Brizzi, L ;
Periti, E ;
d'Agata, A ;
Vanzi, E ;
Cariati, E .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (08) :917-920
[8]  
BONNO M, 1994, LAB INVEST, V71, P560
[9]   SERUM PAPP-A AND FREE BETA-HCG ARE FIRST-TRIMESTER SCREENING MARKERS FOR DOWN-SYNDROME [J].
BRAMBATI, B ;
TULUI, L ;
BONACCHI, I ;
SHRIMANKER, K ;
SUZUKI, Y ;
GRUDZINSKAS, JG .
PRENATAL DIAGNOSIS, 1994, 14 (11) :1043-1047
[10]  
BRAMBATI B, 1986, LANCET, V2, P165